help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spitzer, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spitzer, T. R.
The Oncologist, Vol. 5, No. 3, 215-223, June 2000
© 2000 AlphaMed Press

Nonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism

Thomas R. Spitzer

Bone Marrow Transplant Program, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Thomas R. Spitzer, M.D., Director, Bone Marrow Transplant Program, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts 02114, USA. Telephone: 617-724-1124; Fax: 617 724-1126; e-mail: spitzer.thomas{at}mgh.harvard.edu

Experimental and clinical experiences have demonstrated successsful donor engraftment following nonmyeloablative preparative regimens. These less toxic conditioning strategies may be better tolerated with diminished transplant-related morbidity and mortality. Importantly, the intentional induction of mixed chimerism can be established following nonmyeloablative conditioning. This approach has the potential advantages of inhibiting graft-versus-host disease, presumably secondary to the persistence of host immunoregulatory cells, and providing a platform for the delivery of adoptive cellular immunotherapy with donor leukocyte infusions for patients with an underlying malignancy. This review will describe the preclinical evolution of nonmyeloablative transplant strategies, the rationale for considering these approaches, and the preliminary clinical experience with this novel allogeneic stem cell therapy.

Key Words. Nonmyeloablative therapy • Mixed chimerism • Graft-versus-host disease • Allogeneic transplant




This article has been cited by other articles:


Home page
BloodHome page
M. Girgis, C. Hallemeier, W. Blum, R. Brown, H.-s. Lin, H. Khoury, L. T. Goodnough, R. Vij, S. Devine, M. Wehde, et al.
Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
Blood, April 15, 2005; 105(8): 3035 - 3041.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Y. Jones, A. Steele, J. M. Jones, Y. Marikar, Y. Chang, A. Feliz, R. A. Cahill, and R. A. Good
Nonmyeloablative Bone Marrow Transplantation of BXSB Lupus Mice Using Fully Matched Allogeneic Donor Cells from Green Fluorescent Protein Transgenic Mice
J. Immunol., May 1, 2004; 172(9): 5415 - 5419.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
J. D. Down and M. E. White-Scharf
Reprogramming Immune Responses: Enabling Cellular Therapies and Regenerative Medicine
Stem Cells, January 1, 2003; 21(1): 21 - 32.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. Hummel, D. Wilms, M. Vitacolonna, and M. Zoller
Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host
J. Leukoc. Biol., November 1, 2002; 72(5): 898 - 912.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
I. A. Tabbara, K. Zimmerman, C. Morgan, and Z. Nahleh
Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results
Arch Intern Med, July 22, 2002; 162(14): 1558 - 1566.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Badros, B. Barlogie, C. Morris, R. Desikan, S. R. Martin, N. Munshi, M. Zangari, J. Mehta, A. Toor, M. Cottler-Fox, et al.
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
Blood, May 1, 2001; 97(9): 2574 - 2579.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2000 by AlphaMed Press.